Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease

Department of Paediatrics, University of Oxford, Level 2, Children's Hospital, Oxford OX3 9DU, UK
Archives of Disease in Childhood (Impact Factor: 2.91). 04/2013; 98(4):248-251. DOI: 10.1136/archdischild-2012-303103
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent data have shown that the immune protection evoked by vaccines given in the first years of life progressively weakens, and that this is associated with a higher than expected incidence of vaccine-preventable diseases in adolescents and young adults. Furthermore, the greater circulation of pathogens among adolescents and young adults leads to a high risk of infection in unvaccinated or not fully vaccinated younger children. These findings, together with the availability of vaccines specifically developed to prevent infections that typically occur during adolescence, have induced a number of experts to suggest radical changes in the immunisation schedules usually recommended by health authorities. The most important of these relate pertussis, meningococcal and human papillomavirus vaccines but, although they are based on unexceptionable scientific premises, the suggestions have been only slowly and partially received in most countries, even in those in which vaccination programmes are usually adequately implemented and monitored. Adolescence is a particular period of life characterised by changes in intellectual, moral, physical, emotional and psychological development. All of these can have a considerable impact on compliance with immunisation schedules because the approach to any preventive method no longer entirely depends on parents' and pediatricians' judgements as in the first years of life but is the consequence of a more complex process involving the adolescents' thoughts and opinions, their relationships with their parents, friends and physicians, and the information they receive from the mass media. Every effort should be made to overcome the barriers to adolescent immunisation, including those arising from the adolescents themselves.
    Vaccine 09/2013; 31(46). DOI:10.1016/j.vaccine.2013.08.092 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The European licensure of 4CMenB, the first vaccine licensed to prevent non-epidemic meningococcal B (MenB) disease, marked an important milestone in the fight against meningococcal disease. However, the potential introduction of 4CMenB into the routine infant schedule is complicated by a number of factors. The recent decline in the number of cases of invasive MenB disease in the UK has important implications for cost effectiveness, though the unpredictable nature of meningococcal disease epidemiology (as evidenced by a recent outbreak in MenB disease at Princeton University) means that it is not clear whether this decline will be sustained. The variable waning of antibody levels against each of the four key vaccine components also complicates the assessment of the likely duration and breadth of protection. After considering these factors, the UK Joint Committee on Vaccination and Immunisation (JCVI) released an interim statement in July 2013 indicating that the introduction of 4CMenB to the routine infant schedule was unlikely to be cost effective but highlighted the need for further data on strain coverage and persistence of immunity. This brief editorial discusses the possible role that booster doses of 4CMenB may have in prolonging persistence of immunity.
    Expert Review of Vaccines 01/2014; 13(3). DOI:10.1586/14760584.2014.878654 · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neisseria meningitidis is differentiated into 12 distinct serogroups, of which A, B, C, W, X, and Y are medically most important and represent an important health problem in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Recent epidemiological surveillance has indicated an increase of serogroup Y invasive meningococcal disease in some parts of Europe as shown in the epidemiological data for 2010 and 2011 from various European countries previously published in this journal.11. Bröker M, Jacobsson S, DeTora L, Pace D, Taha M-K. Increase of meningococcal serogroup Y cases in Europe: a reason for concern?. Hum Vaccin Immunother 2012; 8:685 - 8;; PMID: 22508411 [Taylor & Francis Online]View all references,22. Bröker M, Jacobsson S, Kuusi M, Pace D, Simões MJ, Skoczynska A, Taha MK, Toropainen M, Tzanakaki G. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother 2012; 8:1907 - 11;; PMID: 23032167 [Taylor & Francis Online]View all references Here, data from 33 European countries is reported indicating that the emergence of serogroup Y continued in 2012 in various regions of Europe, especially in Scandinavia, while in Eastern and South-Eastern Europe the importance of serogroup Y remained low.
    Human Vaccines & Immunotherapeutics 03/2014; 10(6). DOI:10.4161/hv.28206 · 3.64 Impact Factor
Show more